Document Detail


Comparison of thrombolytic therapy and primary coronary angioplasty with liberal stenting for inferior myocardial infarction with precordial ST-segment depression: immediate and long-term results of a randomized study.
MedLine Citation:
PMID:  9822097     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: The aim of the study was to compare randomly assigned primary angioplasty and accelerated recombinant tissue plasminogen activator (rt-PA), in patients with "high-risk" inferior acute myocardial infarction (ST-segment elevation in the inferior leads and ST-segment depression in the precordial leads). BACKGROUND: The ST-segment depression in the precordial leads is a marker of severe prognosis in patients with inferior myocardial infarction. The comparative outcome of treatment with primary angioplasty or lysis with accelerated rt-PA has not been investigated. METHODS: One hundred and ten patients within 6 h of symptoms were randomized to either treatment. To assess the in-hospital and 1-year outcome of both treatments the following results were compared: death or nonfatal infarction, recurrence of angina, left ventricular ejection fraction (LVEF), and the need for repeat target vessel revascularization (TVR). RESULTS: In patients treated with angioplasty (55) and rt-PA (55) the rate of in-hospital mortality and reinfarction was 3.6% versus 9.1% (p=0.4). Recurrence of angina was 1.8% versus 20% (p=0.002), new TVR was used in 3.6% versus 29.1% (p=0.0003), and the LVEF (%) at discharge was 55.2+/-9.5 versus 48.2+/-9.9 (p=0.0001). There were no hemorrhagic strokes, no emergency coronary artery bypass graft (CABG) and identical (5.5%) need for blood transfusions. At 1 year, the incidence of death, reinfarction or repeat TVR was 11% in the percutaneous transluminal coronary angioplasty (PTCA) group versus 52.7% in the rt-PA group (log-rank 22.38, p < 0.0001). CONCLUSIONS: Primary angioplasty is superior to accelerated rt-PA in terms of both myocardial preservation and reduction of in-hospital complications in patients with inferior myocardial infarction and precordial ST-segment depression. Primary angioplasty also yields a better long-term event-free survival.
Authors:
F Ribichini; G Steffenino; A Dellavalle; V Ferrero; A Vado; M Feola; E Uslenghi
Related Documents :
15201267 - Massive pulmonary embolism with st elevation in leads v1-v3 and successful thrombolysis...
6821897 - The early recognition of right ventricular infarction: diagnostic accuracy of the elect...
3756597 - Electrophysiology and electrocardiology of acute myocardial ischemia.
17461537 - Bupivacaine induced cardiac toxicity mimicking an acute non-st segment elevation myocar...
21080957 - Glucagon-like peptide-1 and the exenatide analogue ac3174 improve cardiac function, car...
19969407 - Survival increases with cpr by emergency medical services before defibrillation of out-...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of the American College of Cardiology     Volume:  32     ISSN:  0735-1097     ISO Abbreviation:  J. Am. Coll. Cardiol.     Publication Date:  1998 Nov 
Date Detail:
Created Date:  1998-12-16     Completed Date:  1998-12-16     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8301365     Medline TA:  J Am Coll Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1687-94     Citation Subset:  AIM; IM    
Affiliation:
Division of Cardiology, Ospedale Santa Croce, Cuneo, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Angioplasty, Transluminal, Percutaneous Coronary*
Coronary Angiography
Electrocardiography*
Female
Fibrinolytic Agents / therapeutic use
Humans
Longitudinal Studies
Male
Middle Aged
Myocardial Infarction / physiopathology*,  radiography,  therapy*
Recombinant Proteins
Stents*
Survival Analysis
Thrombolytic Therapy*
Tissue Plasminogen Activator / therapeutic use
Treatment Outcome
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; 0/Recombinant Proteins; EC 3.4.21.68/Tissue Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effects of therapy with nifedipine GITS or atenolol on mental stress-induced ischemic left ventricul...
Next Document:  Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term pro...